Search


FDA approves LEMBAZ for infantile-onset NPC: what the news means for Australia
The U.S. FDA has approved LEMBAZ™ (adrabetadex) for eligible people with infantile-onset Niemann–Pick disease type C. The decision marks a milestone for a treatment with a long Australian history: local families and advocates helped bring its clinical trial to Australia. Australian approval and availability have not been confirmed.

ANPDF
5 days ago3 min read


What Shionogi’s planned acquisition of IntraBio means for the NPC community
Shionogi has entered into an agreement to acquire IntraBio, the company behind AQNEURSA® (levacetylleucine). Here is what the announcement means—and what we are still waiting to learn—for the Australian NPC community.

ANPDF
Oct 73 min read
